Epigenetic alterations in prostate cancer: the role of chromatin remodeling.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2025-10-01 Epub Date: 2025-07-22 DOI:10.1080/17501911.2025.2535938

Md Sadique Hussain, Yumna Khan, Mudasir Maqbool, Gyas Khan, Wedad Mawkili, Faroq Kamli, Ali Hanbashi, Prawez Alam

{"title":"Epigenetic alterations in prostate cancer: the role of chromatin remodeling.","authors":"Md Sadique Hussain, Yumna Khan, Mudasir Maqbool, Gyas Khan, Wedad Mawkili, Faroq Kamli, Ali Hanbashi, Prawez Alam","doi":"10.1080/17501911.2025.2535938","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) is one of the most common cancers in men, distinguished by a multifaceted pathogenesis that involves substantial epigenetic modifications. This article emphasizes the critical role of chromatin remodeling in PCa advancement. Chromatin remodeling, a key epigenetic mechanism, influences gene expression by modulating the chromatin structure through the action of specialized complexes such as SWI/SNF, ISWI, CHD, & INO80, thereby regulating genes vital to tumor progression. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus databases for studies published between 2000 and 2025, focusing on chromatin remodeling, epigenetic alterations, and therapeutic strategies in PCa. The review discusses the major epigenetic changes observed in PCa, including DNA and RNA methylation, histone modifications, and non-coding RNA (ncRNA)-mediated chromatin remodeling. The evolving epigenetic landscape shaped by these alterations offers insights into novel therapeutic opportunities. The clinical relevance of targeting chromatin remodeling complexes is explored, alongside existing therapies and potential future interventions. This review also addresses challenges in studying chromatin remodeling and highlights emerging technologies that could enhance understanding of PCa epigenetics. This comprehensive exploration underscores the promise of chromatin remodeling as both a biomarker and a therapeutic target in PCa management.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"967-991"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490391/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17501911.2025.2535938","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer (PCa) is one of the most common cancers in men, distinguished by a multifaceted pathogenesis that involves substantial epigenetic modifications. This article emphasizes the critical role of chromatin remodeling in PCa advancement. Chromatin remodeling, a key epigenetic mechanism, influences gene expression by modulating the chromatin structure through the action of specialized complexes such as SWI/SNF, ISWI, CHD, & INO80, thereby regulating genes vital to tumor progression. A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus databases for studies published between 2000 and 2025, focusing on chromatin remodeling, epigenetic alterations, and therapeutic strategies in PCa. The review discusses the major epigenetic changes observed in PCa, including DNA and RNA methylation, histone modifications, and non-coding RNA (ncRNA)-mediated chromatin remodeling. The evolving epigenetic landscape shaped by these alterations offers insights into novel therapeutic opportunities. The clinical relevance of targeting chromatin remodeling complexes is explored, alongside existing therapies and potential future interventions. This review also addresses challenges in studying chromatin remodeling and highlights emerging technologies that could enhance understanding of PCa epigenetics. This comprehensive exploration underscores the promise of chromatin remodeling as both a biomarker and a therapeutic target in PCa management.

查看原文本刊更多论文

前列腺癌的表观遗传改变：染色质重塑的作用。

前列腺癌（PCa）是男性最常见的癌症之一，其发病机制具有多方面，涉及大量的表观遗传修饰。本文强调了染色质重塑在前列腺癌进展中的关键作用。染色质重塑是一种重要的表观遗传机制，通过SWI/SNF、ISWI、CHD和INO80等特殊复合物的作用，通过调节染色质结构来影响基因表达，从而调控肿瘤进展的重要基因。利用PubMed、Web of Science和Scopus数据库对2000年至2025年间发表的研究进行了全面的文献检索，重点是PCa的染色质重塑、表观遗传改变和治疗策略。本文讨论了PCa中观察到的主要表观遗传变化，包括DNA和RNA甲基化，组蛋白修饰和非编码RNA （ncRNA）介导的染色质重塑。由这些改变形成的不断演变的表观遗传景观为新的治疗机会提供了见解。探讨了靶向染色质重塑复合物的临床相关性，以及现有的治疗方法和潜在的未来干预措施。本文还讨论了染色质重塑研究中的挑战，并强调了可以增强对PCa表观遗传学理解的新兴技术。这项全面的探索强调了染色质重塑作为前列腺癌治疗的生物标志物和治疗靶点的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.